Pediatrix Medical Group, Inc.
NYSE:MDMedical - Care Facilities
-$0.48 today
- Market cap
- $2.41B
- Beta
- 0.70
- P/E (TTM)
- 11.0
- EPS (TTM)
- $2.10
Volume 0.64M
Average 0.82M
MD Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Pediatrix Medical Group, Inc.NYSE: MD
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income declines year over year
Q3 FY2026 net income of $46.99M fell 34.5% year over year, behind the -7.5% change in trailing-twelve-month net income. Sequentially, it rose 17.9% from the prior quarter. Over 3 fiscal years it compounded at +38.3% a year.
Context
- Net income amounted to 8.6% of revenue in FY2025, up 3.7 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of $204.08M (+23.4%) for the fiscal year ending Dec 2026, a slowdown from the +266.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $46.99M+17.9% QoQ
- Last fiscal yearDec 2025
- $165.39M+266.9% YoY
- LTMSep 2026
- $150.09M-7.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -34.5% | +49.9% | +84.3 pp |
| 1 year | +266.9% | +23.4% | -243.5 pp |
| 3-year CAGR | +38.3% | +11.3% | -27.0 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 165.39M USD
- Year-over-year change
- +266.9%
- 4-year CAGR
- +11.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 165.39M | +266.9% |
| FY2024 | 2024-12-31 | (99.07M) | -64.0% |
| FY2023 | 2023-12-31 | (60.41M) | -196.5% |
| FY2022 | 2022-12-31 | 62.57M | -42.1% |
| FY2021 | 2021-12-31 | 108.01M | — |
Net Income vs competitors
How MD compares with its peers on the latest reported figures
- MD's LTM Sep 2026 net income of $150.09M is the 5th largest of the 11 companies compared; the peer median is $91.27M.
- Its year-over-year change of -7.5% is the 6th highest of 11, against a peer median of -5.3%.
- Net income amounts to 7.7% of revenue for MD, versus a peer median of 4.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.12B | -1051.3% | — | 32.9% | |
| LTM Oct 2026 | $306.15M | +305.7% | — | 11.4% | |
| LTM Mar 2026 | $196.34M | -22.8% | -9.6% | 3.6% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $186.34M | -23.1% | -4.6% | 2.9% |
| LTM Sep 2026 | $150.09M | -7.5% | +38.3% | 7.7% | |
| LTM Jun 2026 | $130.38M | +57.1% | +27.7% | 8.8% | |
| LTM Sep 2026 | $116.02M | +12.2% | +83.1% | 7.3% | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | $66.52M | +187.8% | -0.3% | 4.5% |
| LTM Jun 2026 | $50.6M | +413.3% | — | 3.2% | |
| LTM Sep 2026 | $40.75M | -108.1% | -41.1% | 0.7% | |
| LTM Mar 2026 | $32.29M | -26.6% | -19.3% | 0.9% | |
| Peer median (excluding MD) | $91.27M | -5.3% | -4.6% | 4.1% | |
Competitors are the stored peer set for MD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 108.01M | 62.57M | (60.41M) | (99.07M) | 165.39M |
| Depreciation & Amortization | 32.15M | 35.64M | 36.17M | 32.23M | 21.83M |
| Deferred Income Tax | (31.24M) | (22.77M) | 3.24M | (2.13M) | 52.19M |
| Stock-Based Compensation | 18.97M | 16.13M | 12.32M | 11.87M | 18.05M |
| Change in Working Capital | (23.36M) | 31.83M | (11.63M) | 88.24M | 41.83M |
| Accounts Receivables | (72.73M) | (5.54M) | 26.28M | 10.29M | 30.56M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 21.33M | 420K | (11.92M) | 51.14M | 28.33M |
| Other Working Capital | 28.05M | 36.95M | (25.98M) | 26.81M | (17.06M) |
| Other Non-Cash Items | (27.8M) | 43.55M | 157.63M | 175.44M | (28.18M) |
| Operating Cash Flow | 76.74M | 166.94M | 137.33M | 206.57M | 271.09M |
| Capital Expenditures | (32.25M) | (29.71M) | (33.33M) | (22.02M) | (18.46M) |
| Acquisitions (Net) | (29.93M) | (28.17M) | (6.67M) | (8.17M) | 6.8M |
| Purchases of Investments | (35.05M) | (17.35M) | (31.89M) | (64.55M) | (29.85M) |
| Sales of Investments | 16.5M | 16.89M | 22.91M | 52.49M | 26.67M |
| Other Investing Activities | 27.66M | 1.38M | 807K | 6.84M | (3.47M) |
| Investing Cash Flow | (53.07M) | (56.95M) | (48.18M) | (35.41M) | (18.3M) |
| Debt Repayment | (762.66M) | (405.17M) | (19.12M) | (15.39M) | (20.75M) |
| Common Stock Issued | 6.85M | 5.4M | 4.91M | 3.64M | 3.18M |
| Common Stock Repurchased | (4.72M) | (88.51M) | (919K) | (1.7M) | (86.68M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 407K | 732K | (10.59M) | (1.03M) | (3.25M) |
| Financing Cash Flow | (760.12M) | (487.55M) | (25.72M) | (14.49M) | (107.49M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (736.45M) | (377.57M) | 63.43M | 156.68M | 145.3M |
| Free Cash Flow | 44.49M | 137.23M | 104M | 184.55M | 252.63M |
Pediatrix Medical Group, Inc.
NYSE:MD
Intrinsic Alpha fair value
Locked
Current Price
$30.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.